2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 6: May 3, 2023 - Navigating the Challenges of Diagnosis and Management of Hidradenitis Suppurativa
Fall Clinical Virtual Grand Rounds consists of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology.
Please join us for this week's session:
Wednesday, May 3, 2023
8 PM ET/ 5 PM PT
Navigating the Challenges of Diagnosis and Management of Hidradenitis Suppurativa
This activity is supported by educational grants from Incyte and UCB
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
May 3, 2023
May 3, 2024
At the completion of this activity, participants should be better able to:
Recall how to diagnose hidradenitis suppurativa (HS)
Describe the pathways for development of HS
Discuss novel therapies in development for the treatment of HS
Jennifer Hsiao, MD
University of Southern California
Los Angeles, CA
Joslyn Kirby, MD
Associate Professor of Dermatology
Penn State Health
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Advisory Board/Consultant: AbbVie, Aclaris, Boheringer Ingelheim, Novartis, UCB
Speaker's Bureau: Abbvie
Grant/Research Support: Incyte
Consultant: AbbVie, Alumis, DermTech, Insmed, Incyte, Janssen
Speakers’ Bureau or Honoraria: AbbVie, Novartis, UCB, Janssen
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.